Physician profile
Faisal Adhami
NPI 1649405549
$2,837.60
in general payments reported to CMS, 2019-2025
52 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.51 · 2020: $89.72 · 2021: $102 · 2022: $521 · 2023: $1,222 · 2024: $672 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000 · Education: $96.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.22 |
| Education | $96.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $216.77 | 2021-2023 | Opdivo |
| Amgen INC. | $184.04 | 2019-2023 | Lumakras, Kyprolis |
| Janssen Biotech, INC. | $173.88 | 2022-2024 | Darzalex, Tecvayli, Balversa |
| Tempus Ai, INC | $150.87 | 2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $134.37 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $101.44 | 2021-2024 | Libtayo |
| Pfizer INC. | $90.57 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $88.30 | 2020-2024 | Enhertu, Imfinzi |
| Alexion Pharmaceuticals, INC. | $88.23 | 2024 | Ultomiris |
| Genentech USA, INC. | $85.58 | 2022-2023 | Perjeta, Lunsumio, Polivy |
| Pharmacyclics LLC, An Abbvie Company | $82.67 | 2022-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $79.45 | 2020-2023 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $78.86 | 2023-2024 | Venclexta |
| Astellas Pharma US INC | $77.41 | 2022-2024 | Padcev, Xtandi |
| Glaxosmithkline, LLC. | $77.20 | 2021-2024 | Ojjaara, Zejula, Jemperli |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Adhami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.